Abstract:Background: All patients with EGFR mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). In up to 30% of patients, the mechanism of acquired resistance remains unknown. MicroRNAs (miRNAs) represent a category of small non-coding RNAs commonly dysregulated in human malignancies and have been implicated in therapy resistance. The aim of this study was to understand the role of novel miRNAs in acquired EGFR TKI resistance in EGFR-mutant NSCLC. Method: The miR-483-3p expression in in vitro and in vivo models of acquired gefitinib resistance was examined by miRNA microarray and real-time RT-PCR. Transient or stable gain- and loss-of-function experiments were conducted in cell lines and nude mice, to evaluate the effects of miR-483-3p on sensitivity to gefitinib, proliferation, apoptosis, EMT and migration/invasion in vitro and in vivo. The molecular pathways affected by miR-483-3p were characterized using in silico target prediction, dual luciferase reporter assays and overexpression rescue experiments. The role of promoter methylation in miR-483-3p silencing was examined by real-time RT-PCR after demethylating agents treatment. Result: In this study, we reported the silencing of miR-483-3p and evidence for epithelial-to-mesenchymal transition (EMT) in both in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to gefitinib. In those tumor models, forced expression of miR-483-3p effectively increased sensitivity of gefitinib-resistant lung cancer cells to gefitinib by inhibiting proliferation, promoting apoptosis and reversing EMT phenotype. Mechanistically, miR-483-3p directly targeted integrin beta3, and thus repressed downstream FAK/Erk signaling pathway. In addition, miR-483-3p silencing in gefitinib-resistant NSCLC was due to hypermethylation of its own promoter. Conclusion: Our study provides a novel mechanism that epigenetic silencing of miR-483-3p promotes acquired EGFR TKI resistance in EGFR-mutant NSCLC by targeting integrin beta3. miR-483-3p may present a promising therapeutic target to overcome acquired resistance.The work was supported by National Natural Science Foundation of China (81372522 and 81773747), Science and Technology Commission of Shanghai Municipality (12ZR1416000 and 12140901400).

High Expression of SLC34A2 Contributes to Chemoresistance of Non-Small Cell Lung Cancer Against Gefitinib: the Critical Role of Mir-124-3p

MiR-128 Reverses the Gefitinib Resistance of the Lung Cancer Stem Cells by Inhibiting the C-Met/pi3k/akt Pathway.

Epigenetic Silencing of Mir-483-3p Promotes Acquired Gefitinib Resistance and EMT in EGFR-mutant NSCLC by Targeting Integrin Β3

MicroRNA-34a Overcomes HGF-mediated Gefitinib Resistance in EGFR Mutant Lung Cancer Cells Partly by Targeting MET.

MiR-142-5p Reverses the Resistance to Gefitinib Through Targeting HOXD8 in Lung Cancer Cells.

Increased MIR31HG Lncrna Expression Increases Gefitinib Resistance in Non-Small Cell Lung Cancer Cell Lines Through the EGFR/PI3K/AKT Signaling Pathway

Circ_0001786 facilitates gefitinib resistance and malignant progression in non-small cell lung cancer via miR-34b-5p/SRSF1

Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance in EGFR-mutant NSCLC by targeting integrin beta3

Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer

MicroRNAs Reduce Tumor Growth and Contribute to Enhance Cytotoxicity Induced by Gefitinib in Non-Small Cell Lung Cancer

MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines

Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer

Foxm1 Mediated Resistance to Gefitinib in Non-Small-Cell Lung Cancer Cells

MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1.

Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis

Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer

MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin

Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5

MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines

The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC

Alteration In Mir-21/Pten Expression Modulates Gefitinib Resistance In Non-Small Cell Lung Cancer